Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORMINEST FE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-approved),Oral contraceptive for women with iron deficiency (due to ferrous fumarate component)
Prevention of pregnancy (FDA-approved)
1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours. Clinical context: steady-state in 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Norethindrone acetate: extensively metabolized in the liver via reduction and conjugation. Active metabolite: norethindrone. Ethinyl estradiol: metabolized via CYP3A4 and conjugation (glucuronidation and sulfation). Undergoes enterohepatic recirculation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal 60-80% as metabolites, fecal 20-30% via bile, unchanged drug <5%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 61% bound to albumin, 36% to SHBG; ethinyl estradiol: 98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 3.6 ± 0.7 L/kg; ethinyl estradiol: 1.8 ± 0.5 L/kg. Reflects distribution to tissues.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: 64% (oral); ethinyl estradiol: 48% (oral) due to first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate impairment; contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B or C; use with caution in Child-Pugh class A; monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche; for adolescents, same dosing as adults after menarche; safety and efficacy established in females of reproductive age.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women; no dosing studies in geriatric population; use not recommended.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction.,Cigarette smoking increases cardiovascular risk; advise not to smoke.,Elevated blood pressure: monitor regularly.,Gallbladder disease: increased risk of cholelithiasis.,Liver tumors: benign and malignant hepatic adenomas reported.,Carbohydrate and lipid metabolism: monitor in diabetics and those with dyslipidemia.,Headache: may worsen or initiate migraine; discontinue if new headache pattern or persistent.,Bleeding irregularities: breakthrough bleeding and spotting are common; evaluate if persistent.,Ocular effects: retinal thrombosis may cause partial or complete loss of vision; discontinue if proptosis, diplopia, or papilledema.,Depression: discontinue if severe or persistent.,Iron overload: contraindicated in patients with hemosiderosis or hemochromatosis (due to ferrous fumarate).
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) in women over 35,Hemosiderosis or hemochromatosis (due to ferrous fumarate)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions with the hormonal components. Iron tablets may cause gastrointestinal upset; taking with food may reduce nausea but can decrease iron absorption. Avoid high-calcium foods with iron pills. Grapefruit juice may increase estrogen levels; limit intake.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
NORMINEST FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent exposure in large epidemiologic studies, but increased risk of cardiovascular and limb anomalies reported with higher doses. Second/third trimester: Androgenic effects causing clitoromegaly, labial fusion, and potential for impaired fetal growth. Postnatal: Possible long-term neurodevelopmental effects.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
NORMINEST FE reduces milk production and quality. Estrogen and progestin are excreted in breast milk. M/P ratio unreported. Use only if benefit outweighs risk; poorest choice for lactation suppression due to thromboembolic risks.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated during pregnancy; no dose adjustment applicable. If inadvertent exposure, discontinue immediately. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) do not apply as drug is not used during pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Norminest FE is a combination oral contraceptive containing norethindrone and ethinyl estradiol with ferrous fumarate (iron) in the placebo pills. The iron component does not provide contraception. Breakthrough bleeding is more common with low-dose formulations. Patients should be counseled that the iron pills are not active hormonal pills. Monitor for signs of thromboembolism, especially in smokers over 35 years old.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time each day. Do not skip doses.,The last row of pills (typically brown) are iron tablets and do not provide contraception.,Use a backup method (e.g., condoms) if you miss two or more active pills.,Common side effects include nausea, breast tenderness, and spotting between periods.,Seek immediate medical attention for leg pain, shortness of breath, or severe headache.,Smoking increases risk of serious cardiovascular side effects, especially if you are over 35.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORMINEST FE vs AFIRMELLE, answered by our medical review team.
NORMINEST FE is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORMINEST FE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORMINEST FE is: 1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORMINEST FE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORMINEST FE is classified as Category C. NORMINEST FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent exposure in large epidemi. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.